Article
Oncology
Alvaro Haroun-Izquierdo, Marianna Vincenti, Herman Netskar, Hanna van Ooijen, Bin Zhang, Laura Bendzick, Minoru Kanaya, Pouria Momayyezi, Shuo Li, Merete Thune Wiiger, Hanna Julie Hoel, Silje Zandstra Krokeide, Veronika Kremer, Geir Tjonnfjord, Stephanie Berggren, Kristina Wikstroem, Pontus Blomberg, Evren Alici, Martin Felices, Bjoern oenfelt, Petter Hoeglund, Bahram Valamehr, Hans-Gustaf Ljunggren, Andreas Bjoerklund, Quirin Hammer, Lise Kveberg, Frank Cichocki, Jeffrey S. Miller, Karl-Johan Malmberg, Ebba Sohlberg
Summary: This study demonstrates the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population for hematological malignancies. The expanded adaptive NK cells retained high cytotoxicity and efficiently killed leukemia cells from AML patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Shayan Rahmani, Niloufar Yazdanpanah, Nima Rezaei
Summary: This article highlights the potential of NK cells for the treatment of AML and discusses the challenges associated with such therapeutic methods. The clinical application of NK cells, primarily in patients with AML, is described based on existing evidence.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Oncology
Michaela Allison, Joel Mathews, Taylor Gilliland, Stephen O. Mathew
Summary: This review describes the functional impairment of NK cells in leukemia and current NK cell immunotherapies under investigation, including mAbs, adoptive transfer, and CAR-NKs. NK cells play a critical role in cancer cell elimination through recognition and cytolysis of abnormal cell populations.
Review
Immunology
Selma Z. D'Silva, Meenakshi Singh, Andrea S. Pinto
Summary: Acute Myeloid Leukemia (AML) is a complex and rapidly progressing disease with poor outcomes. Natural Killer cells have been shown to have potential against AML, but disease-associated defects can limit their effectiveness. Different NK cell therapies, such as adoptive NK cell transfer and CAR-NK cell therapy, have shown promise, but data is limited and outcomes vary. In this mini-review, the role of NK cell defects in AML progression, available therapies, and trial results are discussed.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
P. K. J. D. de Jonge, P. M. M. van Hauten, L. D. Janssen, A. L. de Goede, M. M. Berrien-Elliott, J. M. R. van der Meer, C. M. Mousset, M. W. H. Roeven, M. Foster, N. Blijlevens, W. Hobo, T. A. Fehniger, J. H. Jansen, N. P. M. Schaap, H. Dolstra
Summary: Allogeneic natural killer (NK) cell-based immunotherapy is a promising approach for acute myeloid leukemia (AML). A good manufacturing practice (GMP)-compliant, cytokine-based ex vivo manufacturing process for generating NK cells from CD34(+) hematopoietic stem and progenitor cells (HSPC) has been developed. This process generates a consistent and active NK cell product that meets the requirements for NK cell immunotherapy. The manufactured NK cell batches are used in a clinical trial approved by the Dutch Ethics Committee.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Immunology
Vlad Andrei Cianga, Lydia Campos Catafal, Petru Cianga, Mariana Pavel Tanasa, Mohamad Cherry, Phillipe Collet, Emmanuelle Tavernier, Denis Guyotat, Cristina Rusu, Carmen Mariana Aanei
Summary: The study investigated NK cell maturation in bone marrow under different conditions and found impaired NK cell antitumor response and phenotypic shift in MDS and AML settings. The results suggest immune response failure during myeloid malignancy pathogenesis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Jiacheng Bi, Chen Huang, Xiaomeng Jin, Chaoyue Zheng, Yingying Huang, Xiaohu Zheng, Zhigang Tian, Haoyu Sun
Summary: By analyzing single-cell transcriptomics and using gene reporter mice, this study found that TIPE2 expression correlated with NK cell exhaustion in the tumor microenvironment (TME) in both humans and mice. Deletion of TIPE2 improved the antitumor activity of adoptively transferred mouse NK cells and human NK cells, either derived from peripheral blood or induced pluripotent stem cells (iPSCs). Additionally, TIPE2 deletion synergized with CISH deletion to further enhance antitumor activity in vivo.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Sainiteesh Maddineni, John L. Silberstein, John B. Sunwoo
Summary: This article reviews multiple approaches for allogeneic NK cell therapy and discusses the advantages and disadvantages of each method. In recent years, NK cells have become increasingly important players in the immune response against cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Samantha A. Barnes, Katherine M. Audsley, Hannah V. Newnes, Sonia Fernandez, Emma de Jong, Jason Waithman, Bree Foley
Summary: The study found that IFN alpha 14 and IFN beta are superior activators of NK cell effector function in vitro. It was also shown that NK cells pre-activated with IFN alpha 14 significantly prolonged survival in a preclinical model of leukaemia. These results suggest that further investigation into using IFN alpha 14 to modulate NK cells against leukaemia is promising.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Max Yano, John C. Byrd, Natarajan Muthusamy
Summary: This article reviews the potential and progress of NK cell therapy for CLL, highlighting the immunosuppressive effects of CLL on NK cells as a major limitation to the development of effective treatments. Despite the challenges, NK cell therapy still holds significant therapeutic potential for CLL.
Article
Oncology
Jusuf Imeri, Christophe Desterke, Paul Marcoux, Diana Chaker, Noufissa Oudrhiri, Xavier Fund, Jamila Faivre, Annelise Bennaceur-Griscelli, Ali G. Turhan
Summary: The introduction of TKI therapies has greatly changed the natural history of CML. TKI discontinuation is possible in patients with deep molecular response, but strict molecular follow-up is required to avoid molecular relapse. This case study shows a patient who voluntarily interrupted TKI therapy and remained in deep molecular remission for a long time, potentially due to an immune surveillance phenomenon. Single-cell transcriptome analysis revealed the presence of genes involved in NK-T cell activity and anti-tumor immunity.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Peter J. J. Chockley, Jorge Ibanez-Vega, Giedre Krenciute, Lindsay J. J. Talbot, Stephen Gottschalk
Summary: In this study, researchers aimed to enhance the function of CAR immune cells by tuning the CAR immune synapses using an intracellular scaffolding protein binding site. The results showed that the synapse-tuned CAR immune cells exhibited increased effector cell functionality both in vitro and in vivo, leading to enhanced killing of tumor cells.
NATURE BIOTECHNOLOGY
(2023)
Article
Oncology
Phatchanat Klaihmon, Sudjit Luanpitpong, Xing Kang, Surapol Issaragrisil
Summary: This study successfully engineered a clonal master iPSC carrying a third-generation anti-TIM3 CAR and differentiated it into functional anti-TIM3 CAR-NK cells, demonstrating enhanced anti-tumor activity against TIM3-positive AML cells.
CANCER CELL INTERNATIONAL
(2023)
Review
Immunology
Natasha Mupeta Kaweme, Fuling Zhou
Summary: NK cells play a crucial role in cancer immunotherapy, with various sources and innovative methods being explored to enhance therapeutic NK cell generation and overcome immunosuppressive factors in the tumor microenvironment for improved anti-tumor effects.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian, Antonio Curti
Summary: Recent advances in understanding the pathogenesis of acute myeloid leukemia (AML) have accelerated the discovery of new drugs and innovative therapeutic approaches, with a particular focus on the role of the immune system in AML development. Efforts in immune therapy have shown promise in improving survival rates for AML patients by targeting leukemia stem cells and utilizing various modalities such as T cell therapy, checkpoint blockade, and leukemia vaccines.
FRONTIERS IN ONCOLOGY
(2021)
Article
Rheumatology
Vivian E. Saper, Michael J. Ombrello, Adriana H. Tremoulet, Gonzalo Montero-Martin, Sampath Prahalad, Scott Canna, Chisato Shimizu, Gail Deutsch, Serena Y. Tan, Elaine F. Remmers, Dimitri Monos, Timothy Hahn, Omkar K. Phadke, Elaine Cassidy, Ian Ferguson, Vamsee Mallajosyula, Jianpeng Xu, Jaime S. Rosa Duque, Gilbert T. Chua, Debopam Ghosh, Ann Marie Szymanski, Danielle Rubin, Jane C. Burns, Lu Tian, Marcelo A. Fernandez-Vina, Elizabeth D. Mellins, Jill A. Hollenbach
Summary: Drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in Still's disease patients treated with IL-1/IL-6 inhibitors, with features such as eosinophilia, liver enzyme elevation, and persistent rash. HLA-DRB1*15 haplotypes are significantly enriched in Still's disease with DRESS. Pre-prescription HLA typing and vigilance for serious reactions to these drugs are recommended.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Luciana de Brito Vargas, Marcia H. Beltrame, Brenda Ho, Wesley M. Marin, Ravi Dandekar, Gonzalo Montero-Martin, Marcelo A. Fernandez-Vina, A. Magdalena Hurtado, Kim R. Hill, Luiza T. Tsuneto, Mara H. Hutz, Francisco M. Salzano, Maria Luiza Petzl-Erler, Jill A. Hollenbach, Danillo G. Augusto
Summary: The KIR genes in humans exhibit high diversity, particularly in South American populations, and play a regulatory role in HLA interactions. Studies show that indigenous populations in South America have lower numbers of KIR-HLA interactions, with most relying on a few HLA-C molecules.
MOLECULAR BIOLOGY AND EVOLUTION
(2022)
Review
Oncology
Yaya Chu, Margaret Lamb, Mitchell S. Cairo, Dean A. Lee
Summary: NK cells play a critical role in the treatment of B cell NHL, especially in engaging with rituximab for antibody-dependent cellular cytotoxicity. The emergence of CAR T cell therapies has shown significant efficacy in B cell NHL, but they are difficult to implement due to long manufacturing time, high cost, and toxicities. The renewed interest in NK cell-directed therapies in NHL promises the introduction of new modalities in the near future.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Cell Biology
Kazutoyo Osoegawa, Steven G. E. Marsh, Rhonda Holdsworth, Sebastiaan Heidt, Gottfried Fischer, Cathi Murphey, Martin Maiers, Marcelo A. Fernandez Vina
Summary: HLA serological specificities were defined by the reactivity of HLA molecules with sets of sera and monoclonal antibodies. Many recently identified alleles defined by molecular typing lack their serotype assignment. The correlation between the reactivity of serologic reagents and AA residues was studied, and specific epitopes were identified for different HLA loci. Automated serotype assignments to HLA alleles were developed using HATS software, and additional DEP patterns were identified that do not correspond to any known serologic specificities.
Review
Immunology
Neng Yu, Medhat Askar, Kim Wadsworth, Loren Gragert, Marcelo A. Fernandez-Vina
Summary: This article provides a comprehensive and practical approach to HLA testing to support HCT and highlights donor selection considerations and available online tools.
Article
Immunology
Alin L. Girnita, Lin Wang, Adriana Colovai, Patrick Ahearn, Yorg Azzi, Madhav C. Menon, Marcelo Fernandez-Vina, Howard M. Gebel, E. Steve Woodle, Paolo Cravedi, Jonathan S. Maltzman, Enver Akalin
Summary: This study investigated the changes in anti-HLA antibodies in kidney transplant recipients after COVID-19 and compared them with anti-SARS-CoV-2 antibodies. The results showed that anti-HLA antibodies were mainly IgG, while anti-SARS-CoV-2 antibodies had a high IgA/IgM profile.
Article
Oncology
Marcelo S. F. Pereira, Kinnari Sorathia, Yasemin Sezgin, Aarohi Thakkar, Colin Maguire, Patrick L. L. Collins, Bethany L. L. Mundy-Bosse, Dean A. A. Lee, Meisam Naeimi Kararoudi
Summary: Loss of cytotoxicity and defective metabolism in NK cells from AML patients or healthy donors with IL-15 expansion ex vivo are associated with GSK3 beta overexpression. Inhibition of GSK3 beta improves the function of these NK cells. This study reveals that GSK3 beta deletion does not affect cytotoxicity or maturation, but affects rRNA processing, cell proliferation, and metabolic function, suggesting a potential role of GSK3 beta in metabolic reprogramming of NK cells.
Article
Immunology
Ute V. Solloch, Anette S. Giani, Maria Ignacia Pattillo Garnham, Juergen Sauter, Stefanie N. Bernas, Vinzenz Lange, Francisco Barriga, Marcelo A. Fernandez-Vina, Alexander H. Schmidt
Summary: Hematopoietic stem cell transplantation often requires unrelated stem cell donors matched in HLA genes. The extensive allelic variability of the HLA system complicates donor search, hence the need for large registries. This study analyzed HLA allele and haplotype frequencies of DKMS Chile donors, identifying alleles more abundant in the Chilean subpopulations, particularly in the Mapuche. The study also revealed limited benefits for Chilean patients from non-Chilean donor registries, emphasizing the need for ongoing donor recruitment efforts in Chile.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Oncology
Joseph R. Caporale, Dean A. Lee
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Article
Cell Biology
Maneesh Kumar Misra, Jerome G. Weidner, Rebecca L. Upchurch, Arianne M. Mankey, Marcelo A. Fernandez-Vina, Susana G. Marino
Summary: This study presents a novel approach of using SPT-EDTA serum treatment to reduce background interference in Luminex HLA antibody testing. The effectiveness of SPT-EDTA treatment was compared with ADS and SC-treated sera, and SPT-EDTA treatment showed better results in reducing high background.
Meeting Abstract
Cell Biology
Kerry Kizer, Danillo Augusto, Gonzalo Montero-Martin, Noelle Schlenk, Jacquelyn Horgan, Kristen Wade, Jorge Oksenberg, Marcelo Fernandez-Vina, Jennifer Frankovich, Jill A. Hollenbach
Meeting Abstract
Cell Biology
Katerina Sikorova, Martina Doubkova, Adam Strnad, Lenka Kocourkova, Jana Petrkova, Kazutoyo Osoegawa, Marcelo A. Fernandez-Vina, Martin Petrek
Meeting Abstract
Cell Biology
Kazutoyo Osoegawa, Steven G. E. Marsh, Rhonda Holdsworth, Sebastiaan Heidt, Gottfried Fischer, Cathi Murphey, Martin Maiers, Marcelo Fernandez-Vina
Meeting Abstract
Cell Biology
Katerina Sikorova, Adriana Gavronova, Jana Petrkova, Lenka Kocourkova, Kazutoyo Osoegawa, Marcelo A. Fernandez-Vina, Martin Petrek
Article
Surgery
Vaka K. Sigurjonsdottir, Natasha Purington, Abanti Chaudhuri, Bing M. Zhang, Marcelo Fernandez-Vina, Runolfur Palsson, Neeraja Kambham, Vivek Charu, Kim Piburn, Lynn Maestretti, Anika Shah, Amy Gallo, Waldo Concepcion, Paul C. Grimm
Summary: This retrospective study assessed the performance of risk stratification using systematic donor-specific antibody (DSA) monitoring. The results showed that C1q-dnDSA is more reliable than standard dnDSA in identifying patients at high risk of graft failure.
TRANSPLANT INTERNATIONAL
(2022)